[Edaily Reporter Park Jung-Soo ] #PROTEINA CO., LTD. announced on the 14th that it has decided to acquire an additional 5,700 shares of ABX Biosciences, a company developing AI for new drug design, for 3.42 billion won. The acquisition amount represents 12.05% of the company’s equity, and the scheduled acquisition date is the 16th. Following the acquisition, Protina’s stake will be 26.66% (6,700 shares). The company explained, “We plan to acquire the shares by purchasing already-issued shares and participating in a third-party private placement,” adding, “We are acquiring this stake to strengthen our new drug development capabilities and pursue new business ventures by securing de novo antibody design AI technology.”